Conneally E, Eaves C J, Humphries R K
Terry Fox Laboratory, BC Cancer Agency, Vancouver, BC, Canada.
Blood. 1998 May 1;91(9):3487-93.
Recent studies have shown efficient gene transfer to primitive progenitors in human cord blood (CB) when the cells are incubated in retrovirus-containing supernatants on fibronectin-coated dishes. We have now used this approach to achieve efficient gene transfer to human CB cells with the capacity to regenerate lymphoid and myeloid progeny in nonobese diabetic (NOD)/severe combined immunodeficiency (SCID) mice. CD34(+) cell-enriched populations were first cultured for 3 days in serum-free medium containing interleukin-3 (IL-3), IL-6, granulocyte colony-stimulating factor, Flt3-ligand, and Steel factor followed by two 24-hour incubations with a MSCV-NEO virus-containing medium obtained under either serum-free or serum-replete conditions. The presence of serum during the latter 2 days made no consistent difference to the total number of cells, colony-forming cells (CFC), or long-term culture-initiating cells (LTC-IC) recovered at the end of the 5-day culture period, and the cells infected under either condition regenerated similar numbers of human CD34(+) (myeloid) CFC and human CD19(+) (B lymphoid) cells for up to 20 weeks in NOD/SCID recipients. However, the presence of serum increased the viral titer in the producer cell-conditioned medium and this was correlated with a twofold to threefold higher efficiency of gene transfer to all progenitor types. With the higher titer viral supernatant, 17% +/- 3% and 17% +/- 8%, G418-resistant in vivo repopulating cells and LTC-IC were obtained. As expected, the proportion of NEO + repopulating cells determined by polymerase chain reaction analysis of in vivo generated CFC was even higher (32% +/- 10%). There was no correlation between the frequency of gene transfer to LTC-IC and colony-forming unit-granulocyte-macrophage (CFU-GM), or to NOD/SCID repopulating cells and CFU-GM (r2 = 0.16 and 0.17, respectively), whereas values for LTC-IC and NOD/SCID repopulating cells were highly and significantly correlated (r2 = 0.85). These findings provide further evidence of a close relationship between human LTC-IC and NOD/SCID repopulating cells (assessed using a >/= 6-week CFC output endpoint) and indicate the predictive value of gene transfer measurements to such LTC-IC for the design of clinical gene therapy protocols.
最近的研究表明,当将人脐带血(CB)中的细胞在纤连蛋白包被的培养皿中于含逆转录病毒的上清液中孵育时,能有效地将基因转移至原始祖细胞。我们现在已采用这种方法来实现将基因高效转移至人CB细胞,这些细胞能够在非肥胖糖尿病(NOD)/重症联合免疫缺陷(SCID)小鼠体内再生淋巴样和髓样子代细胞。首先将富含CD34(+)细胞的群体在含有白细胞介素-3(IL-3)、IL-6、粒细胞集落刺激因子、Flt3配体和干细胞因子的无血清培养基中培养3天,随后用在无血清或含血清条件下获得的含MSCV-NEO病毒的培养基进行两次24小时孵育。在培养期后两天血清的存在对5天培养期末回收的细胞总数、集落形成细胞(CFC)或长期培养起始细胞(LTC-IC)没有一致的差异,并且在两种条件下感染的细胞在NOD/SCID受体中长达20周能再生出相似数量的人CD34(+)(髓样)CFC和人CD19(+)(B淋巴样)细胞。然而,血清的存在增加了生产细胞条件培养基中的病毒滴度,这与基因转移至所有祖细胞类型的效率提高两倍至三倍相关。使用较高滴度的病毒上清液,获得了17%±3%和17%±8%的对G418耐药的体内再增殖细胞和LTC-IC。正如预期的那样,通过对体内产生的CFC进行聚合酶链反应分析确定的NEO +再增殖细胞比例甚至更高(32%±10%)。基因转移至LTC-IC的频率与粒细胞-巨噬细胞集落形成单位(CFU-GM)之间,或与NOD/SCID再增殖细胞和CFU-GM之间均无相关性(r2分别为0.16和0.17),而LTC-IC和NOD/SCID再增殖细胞的值高度显著相关(r2 = 0.85)。这些发现进一步证明了人LTC-IC与NOD/SCID再增殖细胞之间(使用≥6周的CFC输出终点进行评估)的密切关系,并表明对此类LTC-IC进行基因转移测量对于临床基因治疗方案设计的预测价值。